ACI Archean Chemical Industries Q3 FY25 results (Oct–Dec 2024) and concall
Archean Chemical reported a resilient Q3 FY25 with increased total income and operational profit, alongside an improved EBITDA margin, despite challenging macroeconomic conditions and short-term demand moderation. The company made significant progress on strategic initiatives, including the groundbreaking of its semiconductor facility and continued ramp-up of bromine derivatives. Management expressed confidence in future growth, driven by new client acquisitions and operational efficiencies, while navigating pricing pressures and supply chain issues.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 238 | 243 |
| EBITDA | 76 | 84 |
| Net profit | 22 | 56 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
